Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 12/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465658 | 0.83 | BRAF (0.53) | SRCMAPK12MAPK14BRAF | |
| SCHEMBL15022843 | 0.81 | MAPK12 (0.63) | SRCMAPK12MAPK14HCKBRAF | |
| SCHEMBL9994902 | 0.79 | HCK (0.47) | SRCMAPK12MAPK14HCKIDO1 | |
| SCHEMBL12847081 | 0.72 | SRC (0.48) | SRCMAPK12MAPK14HCKIDO1 | |
| SCHEMBL30012894 | 0.71 | PDPK1 (0.44) | SRCMAPK12MAPK14HCKBRD4 | |
| SCHEMBL12847421 | 0.70 | BRAF (0.46) | SRCMAPK12MAPK14HCKBRAF | |
| SCHEMBL30013014 | 0.68 | KDM4E (0.44) | SRCMAPK12MAPK14HCKBRD4 | |
| SCHEMBL4687323 | 0.68 | IDO1 (0.68) | IDO1EP300KAT8KDM4E | |
| SCHEMBL4281520 | 0.68 | KDR (0.47) | IDO1EP300KAT8 | |
| SCHEMBL2929800 | 0.68 | HCK (0.49) | SRCMAPK12MAPK14HCKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-2582700-B1 | RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| EP-2582700-B1 | RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| EP-2582700-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | Respivert Limited (GB) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011158044-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011158044-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | SRC 4267/4885MAPK12 2494/4885MAPK14 2307/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | SRC 4267/4885MAPK12 2494/4885MAPK14 2307/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | SRC 4267/4885MAPK12 2494/4885MAPK14 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.